Trials / Recruiting
RecruitingNCT06605404
Pan-tumor MRD Study
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,350 (estimated)
- Sponsor
- Paradigm Health · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Esophageal Cancer
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Melanoma (Skin Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- Pancreatic (Exocrine Only)
- Mix of Solid Tumors (MOST)
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | blood and tissue samples | routine standard of care |
| OTHER | blood and tissue samples | Routine standard of care |
Timeline
- Start date
- 2025-01-08
- Primary completion
- 2031-12-01
- Completion
- 2032-04-01
- First posted
- 2024-09-20
- Last updated
- 2025-08-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06605404. Inclusion in this directory is not an endorsement.